好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Association of Fenfluramine Treatment and Everyday Executive Functioning in Adult Patients with Lennox-Gastaut Syndrome
Epilepsy/Clinical Neurophysiology (EEG)
P10 - Poster Session 10 (8:00 AM-9:00 AM)
10-003

Describe everyday executive function (EEF) changes associated with fenfluramine treatment in adults with Lennox-Gastaut syndrome (LGS) using the Behavior Rating Inventory of Executive Functioning®—Adult Version (BRIEF®—A).

Previous post hoc analysis of a fenfluramine LGS randomized clinical trial (RCT) demonstrated EEF improvements in adults treated with fenfluramine (combined doses) versus placebo.

Patients with LGS (2–35y) were randomized (14-week RCT, NCT03355209) to fenfluramine 0.7mg/kg/d (maximum 26mg/d), 0.2mg/kg/d, or placebo; then, could enter the open-label extension (OLE; fenfluramine 0.2mg/kg/d flexibly titrated up to 0.7mg/kg/d).

Baseline and RCT end-of-study (Day 99) or OLE Month 12 caregiver-completed BRIEF®—A were required for data inclusion. Clinically meaningful improvement/worsening (Reliable Change Index≥90%/≥80%) in median BRIEF®—A T-scores (Behavioral Regulation Index [BRI], Metacognition Index [MI], Global Executive Composite [GEC]), changes in T≥65 patient frequency, and Spearman’s correlations between change in seizures associated with a fall and T-scores were analyzed.

RCT and OLE data from 67 (fenfluramine [0.7mg/kg/d, n=18; 0.2mg/kg/d, n=24]; placebo, n=25) and 41 adults with LGS, respectively, were included.

A greater percentage of RCT fenfluramine-treated and OLE patients had median T-score improvements versus placebo (BRI: 17%–33%, 26%–39% versus 12%; MI: 33%, 39%–47% versus 4%; GEC: 28%–38%, 42%–44% versus 8%).

Baseline BRI, MI, and GEC T≥65 frequencies were 25%–33%, 44%–67%, and 36%–56%. MI and GEC T≥65 frequencies decreased with fenfluramine treatment and increased in the placebo group. In OLE, all BRIEF®—A Indexes/Composite frequencies decreased.

Correlations between change in frequency of seizures associated with a fall and BRIEF®—A Indexes/Composite were negligible to weak (RCT: −0.232 to 0.024; OLE: −0.239 to −0.206).

Adults with LGS treated with fenfluramine had clinically meaningful EEF improvements during a 14-week RCT and its 12-month OLE. Reductions in seizures associated with a fall and EEF improvements were partially independent of each other.

Authors/Disclosures
Heidi L. Henninger, MD, FAAN
PRESENTER
Dr. Henninger has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB.
Delphine Breuillard, PhD Dr. Breuillard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biocodex. Dr. Breuillard has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Breuillard has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biocodex. Dr. Breuillard has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Jazz Pharmaceuticals.
Kelly G. Knupp, MD (Children's Hospital Colorado) The institution of Dr. Knupp has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Harmony. Dr. Knupp has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Epilepsy Research.
Adam Strzelczyk Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Angelini. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bicodex. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Desitin. Adam Strzelczyk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Jazz. Adam Strzelczyk has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Takeda. Adam Strzelczyk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Adam Strzelczyk has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UNEEG.
Danielle M. Andrade, MD (University of Toronto) The institution of Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for UCB. Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Jazz Pharmaceutical. The institution of Dr. Andrade has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Stoke Therapeutics. The institution of Dr. Andrade has received research support from Epilepsy Canada. The institution of Dr. Andrade has received research support from SynGAP Research Fund. Dr. Andrade has received publishing royalties from a publication relating to health care. Dr. Andrade has a non-compensated relationship as a Former Chair of task force on Transition with International League Against Epilepsy that is relevant to AAN interests or activities. Dr. Andrade has a non-compensated relationship as a President with Canadian League Against Epilepsy that is relevant to AAN interests or activities.
Patrick Healy, MS Mr. Healy has stock in UCB Biosciences.
Jayne Abraham, PhD Dr. Abraham has received personal compensation for serving as an employee of UCB. Dr. Abraham has stock in UCB.
Amelie Lothe, PhD Dr. Lothe has received personal compensation for serving as an employee of UCB. Dr. Lothe has stock in UCB.
Rima Nabbout (Université Paris Cité) Rima Nabbout has nothing to disclose.